Science 37 Holdings, Inc. (SNCE) Bundle
A Brief History of Science 37 Holdings, Inc. (SNCE)
Formation and Early Years
Science 37 Holdings, Inc., commonly referred to as Science 37, was founded in 2014. The company emerged with a vision to transform clinical trials through a decentralized model, which allows for more efficient patient enrollment and data collection from diverse populations.
Initial Funding and Growth
In 2015, Science 37 raised $7.5 million in a Series A funding round led by the venture capital firm, HLM Venture Partners. The company utilized this funding to enhance its technology platform and expand its service offerings.
Expansion of Services
By 2018, the company had grown significantly and expanded its offerings to include services for therapeutic areas such as oncology, neurology, and infectious diseases. Science 37's decentralized approach became increasingly recognized as a vital component in clinical research.
Public Offering
In March 2021, Science 37 went public through a merger with a special purpose acquisition company (SPAC), Stable Road Acquisition Corp, at an initial valuation of approximately $1.3 billion. The transaction was completed with a PIPE investment of $125 million.
Financial Performance
As of Q3 2023, Science 37 reported significant financial metrics:
| Financial Metric | Q3 2023 Amount |
|---|---|
| Revenue | $40.5 million |
| Net Income | ($25.3 million) |
| Research and Development Expenses | $15.2 million |
| Operating Expenses | $35.7 million |
| Cash and Cash Equivalents | $85 million |
Challenges and Market Position
Despite the rapid growth, Science 37 faced challenges such as increased competition and the need for constant innovation in technology. Nevertheless, it established itself as a leader in decentralized clinical trials, collaborating with major pharmaceutical companies.
Strategic Partnerships and Collaborations
Throughout its history, Science 37 has formed strategic partnerships with several notable organizations, including:
- Pfizer
- AstraZeneca
- Novartis
- Roche
Recent Developments
In early 2023, Science 37 announced a collaboration with eClinical Solutions to enhance its data management capabilities, reflecting its dedication to data integrity and patient-centric study designs.
Market Outlook
The decentralized clinical trial market is projected to grow significantly, with estimates suggesting it could reach $8 billion by 2025. Science 37 aims to capture a substantial share of this market by continuing to innovate.
Stock Performance
As of October 2023, Science 37’s stock (SNCE) has experienced fluctuations. Key stock statistics include:
| Date | Stock Price ($) | Market Capitalization ($ billion) |
|---|---|---|
| October 1, 2023 | $3.25 | $0.75 |
| October 15, 2023 | $3.10 | $0.72 |
| October 31, 2023 | $3.45 | $0.80 |
Conclusion of Chapter
Science 37 Holdings has established a strong foundation in the clinical trial sector, leveraging technology to improve patient access and trial efficiency. The company continues to adapt and innovate in a rapidly evolving market.
A Who Owns Science 37 Holdings, Inc. (SNCE)
Corporate Structure
Science 37 Holdings, Inc. is a publicly traded company listed on the NASDAQ under the ticker symbol SNCE. The company's ownership structure consists of institutional investors, retail investors, and insiders, with varying stakes in the company.
Major Shareholders
As of the latest data from October 2023, the following table outlines the major shareholders of Science 37 Holdings, Inc., including their ownership percentages:
| Shareholder | Ownership Percentage | Shares Owned | Type of Investor |
|---|---|---|---|
| BlackRock, Inc. | 11.5% | 3,200,000 | Institutional Investor |
| The Vanguard Group, Inc. | 10.3% | 2,900,000 | Institutional Investor |
| Wellington Management Company, LLP | 8.7% | 2,400,000 | Institutional Investor |
| Insider Ownership (Total) | 5.2% | 1,500,000 | Insider |
| Other Institutional Investors | 30.0% | 8,400,000 | Institutional Investor |
| Retail Investors | 34.3% | 9,600,000 | Retail Investor |
Insider Shareholdings
Key insiders and their respective holdings are crucial for understanding management's influence on the company:
| Insider Name | Position | Shares Owned | Ownership Percentage |
|---|---|---|---|
| David H. Brendel | CEO | 600,000 | 2.2% |
| Michael A. McGowan | CFO | 300,000 | 1.1% |
| Thomas S. McCarthy | COO | 400,000 | 1.5% |
| Board of Directors (Total) | 200,000 | 0.7% |
Institutional Ownership Trends
The institutional ownership of Science 37 Holdings, Inc. demonstrates a growing interest from major investment firms:
| Year | Institutional Ownership Percentage | Total Shares Held |
|---|---|---|
| 2021 | 28.4% | 7,200,000 |
| 2022 | 32.5% | 8,500,000 |
| 2023 | 40.0% | 9,300,000 |
Stock Performance and Market Capitalization
As of October 2023, Science 37 Holdings, Inc. has shown considerable market activity, impacting its financial valuation:
| Date | Stock Price (USD) | Market Capitalization (USD millions) | Price-to-Earnings Ratio |
|---|---|---|---|
| October 1, 2023 | 8.50 | 220 | 15.5 |
| September 1, 2023 | 7.80 | 210 | 14.2 |
| August 1, 2023 | 9.00 | 230 | 16.0 |
Conclusion on Ownership Structure
The current ownership distribution of Science 37 Holdings, Inc. reflects a diverse mix of institutional and retail investors, with key insiders maintaining a significant presence in the company's equity. This structure is indicative of the strong interest in the company's potential growth in the clinical trial and research landscape.
Science 37 Holdings, Inc. (SNCE) Mission Statement
Vision and Purpose
Science 37 Holdings, Inc. is dedicated to transforming clinical research by delivering patient-centric solutions that enhance the speed, efficiency, and quality of clinical trials. The company’s mission is underscored by the commitment to democratize access to clinical research and improve overall health outcomes for patients.
Core Values
- Integrity: Upholding the highest standards of ethical practice.
- Innovation: Embracing change and pioneering new methodologies in clinical research.
- Collaboration: Building strong partnerships with stakeholders to drive results.
- Excellence: Committing to superior service and outcomes in every project.
Financial Overview
As of the third quarter of 2023, Science 37 reported a revenue of $36.2 million, a 15% increase compared to the same period in the previous year. The company’s operating expenses totaled $32.1 million, leading to an operating loss of $8.5 million. The net loss attributable to common stockholders for the same period was reported at $9.1 million.
Market Position
Science 37 Holdings operates in the global clinical trials market, which is projected to grow to $65 billion by 2027, representing a compound annual growth rate (CAGR) of 5.3%. Science 37’s innovative approach positions it to capture a significant share of this market, particularly in decentralized clinical trials.
Recent Achievements
In 2023, Science 37 expanded its partnerships, securing contracts with three major pharmaceutical companies, which are valued at a combined $16 million over the next five years. Furthermore, the company was recognized for excellence in clinical trial execution, receiving the Clinical Trial Excellence Award in June 2023.
Primary Offerings
Science 37 specializes in the following key areas:
- Decentralized Clinical Trials: Implementing remote patient monitoring and engagement.
- Site Management: Providing comprehensive site operations support.
- Patient Recruitment: Utilizing advanced technologies to enhance participant recruitment and retention.
Employee Engagement and Culture
With over 500 employees as of Q3 2023, Science 37 has an employee satisfaction rate of 89%, according to recent internal surveys. The company invests in continuous professional development, dedicating approximately $2.2 million annually to training and employee well-being programs.
Table: Key Financial Metrics
| Metric | Q3 2022 | Q3 2023 | Change (%) |
|---|---|---|---|
| Revenue | $31.6 million | $36.2 million | +15% |
| Operating Expenses | $28.0 million | $32.1 million | +14.6% |
| Operating Loss | $7.3 million | $8.5 million | +16.4% |
| Net Loss | $8.0 million | $9.1 million | +13.8% |
| Employee Count | 450 | 500 | +11.1% |
Outlook and Future Directions
Science 37 aims to enhance its technological capabilities, focusing on artificial intelligence and machine learning to optimize clinical trials. The company's strategic plan for 2024 includes further expansion into international markets, with targeted revenue growth of 20% year-over-year.
How Science 37 Holdings, Inc. (SNCE) Works
Overview of Science 37 Holdings, Inc.
Science 37 Holdings, Inc. (SNCE) operates a decentralized clinical trial platform, leveraging technology to improve patient participation and data collection. The company's infrastructure allows for remote monitoring and data collection, facilitating clinical trials without the necessity of physical sites.
Business Model
SNCE's business model encompasses the following key components:
- Direct-to-patient trials
- Site optimization through a virtual approach
- Use of telehealth technologies
- Integration of electronic data capture systems
Financial Performance
As of the latest financial statement in Q2 2023, Science 37 reported the following:
| Financial Metric | Q2 2023 | Q2 2022 |
|---|---|---|
| Total Revenue | $14.2 million | $10.5 million |
| Net Loss | ($8.0 million) | ($6.9 million) |
| Operating Expenses | $20.0 million | $15.0 million |
| Cash and Cash Equivalents | $50 million | $25 million |
Market Position
As of October 2023, Science 37 has positioned itself within the rapidly growing market for decentralized clinical trials. The estimated market size for decentralized clinical trials is projected to reach approximately $10 billion by 2026, with a CAGR of around 8.5%.
Key Partnerships
Science 37 has established collaborations with major pharmaceutical companies and research institutions, enhancing their capabilities in conducting trials efficiently. Notable partnerships include:
- Pfizer
- Novartis
- Roche
Technological Innovations
The company utilizes various technologies to streamline the clinical trial process, such as:
- Telehealth for virtual patient engagement
- Remote monitoring devices for real-time data collection
- Wearable technologies to track patient health metrics
Regulatory Compliance
Science 37 maintains compliance with regulatory standards from bodies such as the FDA and EMA. They ensure adherence to Good Clinical Practice (GCP) and implement robust data protection measures.
Clinical Trial Statistics
Science 37's operational statistics indicate:
| Metric | 2023 | 2022 |
|---|---|---|
| Number of Trials Conducted | 75 | 60 |
| Patient Enrollment | 15,000 | 11,000 |
| Average Recruitment Period | 4 months | 6 months |
| Patient Retention Rate | 85% | 80% |
Future Outlook
The company aims to expand its market reach by enhancing its technological offerings and increasing collaborations within the pharmaceutical industry. With growing demand for decentralized trials, Science 37 is positioned for substantial growth in the coming years.
How Science 37 Holdings, Inc. (SNCE) Makes Money
Business Model Overview
Science 37 Holdings, Inc. operates primarily in the clinical research sector, providing a decentralized clinical trial solution. The company leverages technology to streamline the clinical trial process, thereby reducing costs and improving patient engagement.
Revenue Streams
- Clinical Trial Services
- Operational Support
- Technology Solutions
- Consulting Services
Clinical Trial Services
Science 37 earns a significant portion of its revenue through clinical trial services. These services include patient recruitment, site management, and data collection. As of Q2 2023, the company reported revenues of approximately $24 million from clinical trial services, indicating a growth of 30% year-over-year.
| Year | Revenue from Clinical Trials ($ Million) | Year-over-Year Growth (%) |
|---|---|---|
| 2021 | 15 | 40 |
| 2022 | 18.5 | 23.33 |
| 2023 | 24 | 30 |
Operational Support
The company also generates revenue through operational support services, including project management and regulatory affairs. In FY 2022, revenue from operational support was reported at approximately $10 million.
Technology Solutions
Science 37 develops and licenses proprietary technology platforms that support virtual and decentralized trials. Revenue from technology solutions was recorded at around $5 million in FY 2022, with expectations for growth due to increased digitalization in the clinical trial landscape.
| Technology Revenue ($ Million) | Year | Projection for 2024 ($ Million) |
|---|---|---|
| 5 | 2022 | 8 |
| 6 | 2023 | 10 |
Consulting Services
In addition, Science 37 offers consulting services to pharma and biotech companies looking to optimize trial designs. The revenue from consulting services was about $3 million in 2022, with projected growth as more companies seek expertise in decentralized trials.
Partnerships and Collaborations
Strategic partnerships with pharmaceutical firms have been crucial. In 2023, the company announced a collaboration with a leading pharmaceutical company valued at $12 million, which will enhance its service offerings and expand its market reach.
Financial Performance Metrics
As of the end of Q2 2023, Science 37 reported a total revenue of approximately $36 million, with a gross margin of 25%, reflecting operational efficiencies achieved through technology integration.
| Metric | Value |
|---|---|
| Total Revenue ($ Million) | 36 |
| Gross Margin (%) | 25 |
| Net Income ($ Million) | -7 |
Market Position
Science 37 holds a competitive position in the decentralized clinical trials market, which is projected to reach $10 billion by 2026, with a CAGR of 11.3% from 2021 to 2026, presenting substantial revenue growth opportunities.
Science 37 Holdings, Inc. (SNCE) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support